Current Management of Metastatic Brain Disease

Neurotherapeutics

Volumn 6, Issue 3, 2009, Pages 598-603

  Ranjan, Tulika ^a   Abrey, Lauren E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brain metastases; brain metastasis chemotherapy; brain metastasis radiotherapy; brain neoplasm; metastatic brain tumor

Indexed keywords

ALPHA INTERFERON; BROXURIDINE; CARBOPLATIN; CELECOXIB; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EFAPROXIRAL; ETOPOSIDE; FLUOROURACIL; GADOLINIUM TEXAPHYRIN; GEFITINIB; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 2 DERIVATIVE; IRINOTECAN; LONIDAMINE; METHOTREXATE; METRONIDAZOLE; MISONIDAZOLE; NAVELBINE; PACLITAXEL; PREDNISONE; TEMOZOLOMIDE; THALIDOMIDE; VINBLASTINE; VINCRISTINE;

ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MEGADOSE; EDEMA; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STEREOTAXIC SURGERY;

BRAIN; BRAIN NEOPLASMS; DRUG THERAPY; HUMANS; NEOPLASM METASTASIS; NEUROSURGICAL PROCEDURES; RADIOSURGERY; RADIOTHERAPY;

EID: 67649086209     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2009.04.012     Document Type: Article

References (57)

1. Patchell R. Brain metastases. Handb Neurol 25 (1997) 135
2. Posner J.B. Management of brain metastases. Rev Neurol (Paris) 148 (1992) 477-487
3. Sawaya R., and Bindal R.K. Metastatic brain tumors. In: Kaye A.H., and Laws E.R. (Eds). Brain tumors. 2nd ed. (2001), Churchill Livingstone, Edinburgh 999-1026
4. Graus F., Walker R.W., and Allen J.C. Brain metastases in children. J Pediatr 103 (1983) 558-561
5. Wen P.Y., and Loeffler J.S. Management of brain metastases. Oncology 13 (1999) 941-954
6. Johnson J.D., and Young B. Demographics of brain metastasis. Neurosurg Clin N Am 7 (1996) 337-344
7. In: Raizer J.J., and Abrey L.E. (Eds). Brain metastases (2007), Springer, New York
8. Lin N.U., and Winer E.P. Brain metastases: the HER2 paradigm. Clin Cancer Res 13 (2007) 1648-1655
9. Stemmler J., Schmitt M., Willems A., et al. Brain metastases in HER-2 overexpressing metastatic breast cancer: comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. J Clin Oncol 24 (2006) 64s (abstract)
10. Pestalozzi B.C., and Brignoli S. Trastuzumab in CSF. J Clin Oncol 18 (2000) 2349-2351
11. Sirven J.I., Wingerchuk D.M., Drazkowski J.F., Lyons M.K., and Zimmerman R.S. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 79 (2004) 1489-1494
12. Shehata M.K., Young B., Reid B., et al. Stereotactic radiosurgery of 468 brain metastases ≤2 cm: implications for SRS dose and whole brain radiation therapy. Int J Radiat Oncol Biol Phys 59 (2004) 87-93
13. Patchell R.A., Tibbs P.A., Regine W.F., et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280 (1998) 1485-1489
14. Cairncross J.G., Kim J.H., and Posner J.B. Radiation therapy for brain metastases. Ann Neurol 7 (1980) 529-541
15. Byrne T.N., Cascino T.L., and Posner J.B. Brain metastasis from melanoma. J Neurooncol 1 (1983) 313-317
16. Cascino T.L., Leavengood J.M., Kemeny N., and Posner J.B. Brain metastases from colon cancer. J Neurooncol 1 (1983) 203-209
17. Gay P.C., Litchy W.J., and Cascino T.L. Brain metastasis in hypernephroma. J Neurooncol 5 (1987) 51-56
18. Li J., Bentzen S.M., Renschler M., and Mehta M.P. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 25 (2007) 1260-1266
19. Rades D., Haatanen T., and Schild S.E. Dose escalation beyond 30 grays in 10 fractions for patients with multiple brain metastases. Cancer 110 (2007) 1345-1350
20. Gaspar L., Scott C., Rotman M., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37 (1997) 745-751
21. Kurtz J.M., Gelber R., Brady L.W., Carella R.J., Cooper J.S., and Radiation Therapy Oncology Group. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7 (1981) 891-895
22. Mehta M.P., Rodrigus P., Terhaard C.H., et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21 (2003) 2529-2536
23. Suh J.H., Stea B., Nabid A., et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 24 (2006) 106-114
24. Cerchietti L.C., Bonomi M.R., Navigante A.H., Castro M.A., Cabalar M.E., and Roth B.M. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. J Neurooncol 71 (2005) 73-81
25. Tishler R.B., Schiff P.B., Geard C.R., and Hall E.J. Taxol: a novel radiation sensitizer. Cancer Res 52 (1992) 3495-3497
26. DeAngelis L.M., Currie V.E., Kim J.H., et al. The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neurooncol 7 (1989) 241-247
27. Eyre H.J., Ohlsen J.D., Frank J., et al., Southwest Oncology Group. Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. A Southwest Oncology Group study. J Neurooncol 2 (1984) 325-330
28. Komarnicky L.T., Phillips T.L., Martz K., Asbell S., Isaacson S., and Urtasun R. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 20 (1991) 53-58
29. Phillips T.L., Scott C.B., Leibel S.A., Rotman M., and Weigensberg I.J. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 33 (1995) 339-348
30. Conill C., Berenguer J., Vargas M., et al. Incidence of radiation-induced leukoencephalopathy after whole brain radiotherapy in patients with brain metastases. Clin Transl Oncol 9 (2007) 590-595
31. DeAngelis L.M., Delattre J.Y., and Posner J.B. Radiation-induced dementia in patients cured of brain metastases. Neurology 39 (1989) 789-796
32. Simonová G., Liscák R., Novotný Jr. J., and Novotný J. Solitary brain metastases treated with the Leksell gamma knife: prognostic factors for patients. Radiother Oncol 57 (2000) 207-213
33. Vogelbaum M.A., Angelov L., Lee S.Y., Li L., Barnett G.H., and Suh J.H. Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg 104 (2006) 907-912
34. Varlotto J.M., Flickinger J.C., Niranjan A., Bhatnagar A.K., Kondziolka D., and Lunsford L.D. Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 57 (2003) 452-464
35. Xu N., Shu H., Marcus R., and Crocker I.R. Radiation necrosis after stereotactic radiosurgery for metastatic brain disease. Int J Radiat Oncol Biol Phys 69 (2007) S163 (abstract)
36. Müller-Riemenschneider F., Bockelbrink A., et al. Stereotactic radiosurgery for the treatment of brain metastases. Radiother Oncol 91 (2009) 67-74
37. Moser R.P., and Johnson M.L. Surgical management of brain metastases: how aggressive should we be?. Oncology 3 (1989) 123-127
38. Patchell R.A., Tibbs P.A., Walsh J.W., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322 (1990) 494-500
39. Vecht C.J., Haaxma-Reiche H., Noordijk E.M., et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol 33 (1993) 583-590
40. Mintz A.H., Kestle J., Rathbone M.P., et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78 (1996) 1470-1476
41. Andrews D.W., Scott C.B., Sperduto P.W., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363 (2004) 1665-1672
42. Kondziolka D., Patel A., Lunsford L.D., et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45 (1999) 427-434
43. Huang K., Sneed P.K., Kunwar S., et al. Surgical resection and permanent iodine-125 brachytherapy for brain metastases. J Neurooncol 91 (2009) 83-93
44. Ewend M.G., Brem S., Gilbert M., et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res 13 (2007) 3637-3641
45. Cortot A.B., Gerinière L., Robinet G., et al., Groupe Lyon-Saint-Etienne d'Oncologie Thoracique, Groupe Français de Pneumo-Cancérologie. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol 17 (2006) 1412-1417
46. Wu C., Li Y.L., Wang Z.M., Li Z., Zhang T.X., and Wei Z. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 57 (2007) 359-364
47. Chiu C.H., Tsai C.M., Chen Y.M., Chiang S.C., Liou J.L., and Perng R.P. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47 (2005) 129-138
48. Bernardo G., Cuzzoni Q., Strada M.R., et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest 20 (2002) 293-302
49. Fujita A., Fukuoka S., Takabatake H., Tagaki S., and Sekine K. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 59 (2000) 291-295
50. Rosner D., Nemoto T., and Lane W.W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58 (1986) 832-839
51. Boogerd W., Dalesio O., Bais E.M., and van der Sande J.J. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 69 (1992) 972-978
52. Franciosi V., Cocconi G., Michiara M., et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non-small cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85 (1999) 1599-1605
53. Abrey L.E., Olson J.D., Raizer J.J., et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53 (2001) 259-265
54. Lassman A.B., Abrey L.E., Shah G.D., et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 78 (2006) 255-260
55. Ron I.G., Sarid D., Ryvo L., et al. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. Melanoma Res 16 (2006) 65-69
56. Atkins M.B., Sosman J.A., Agarwala S., et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 113 (2008) 2139-2145
57. Bafaloukos D., Tsoutsos D., Fountzilas G., et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res 14 (2004) 289-294